Interaction of macrophages and synthetic polyanions in the inflammatory response

  • H. U. Schorlemmer
  • U. Hadding
  • D. Bitter-Suermann
Part of the Inflammation: Mechanisms and Treatment book series (FTIN, volume 4)


Polyanions are, within the immunological field, of considerable interest. They exert a variety of functions on both humoral and cellular levels. Dextran sulphate (DS), for example, is known to activate the alternative pathway of complement1,2 and interacts with components of the classical pathway3,4. It is known to replace T cell function and to trigger B cell activation5,6. In addition, polyanions gained interest because of their macrophage activating effect7,8 and their anti-viral and anti-tumour activity9,10. In previous publications we described a relationship of the capacity of some polyanions such as carragee-nins or dextran sulphates of different molecular weights and degrees of sul-phation to induce chronic inflammatory responses in vivo, to activate macrophages so that they secrete enzymes and kill tumour cells7,11,12.


Lysosomal Enzyme Enzyme Secretion Mouse Peritoneal Macrophage Dextran Sulphate Acid Hydrolase 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Hadding, U., Dierich, M., König, W., Limber, M., Schorlemmer, H.U. and Bitter-Suermann, D. (1973). Ability of the T-cell-replacing polyanion dextran sulfate to trigger the alternative pathway of complement activation. Eur. J. Immunol., 3,527PubMedCrossRefGoogle Scholar
  2. 2.
    Burger, R., Hadding, U., Schorlemmer, H. U., Brade, V. and Bitter-Suermann, D. (1975). Dextran-sulphate: a synthetic activator of C3 via the alternative pathway. Immunology, 29, 549PubMedGoogle Scholar
  3. 3.
    Loos, M., Volanakis, J. E. and Stroud, R. M. (1976). Mode of interaction of different poly-anions with the first, the second and the fourth component of complement. III. Immunoche-mistry, 13, 789CrossRefGoogle Scholar
  4. 4.
    Loos, M. and Bitter-Suermann, D. (1976). Mode of interaction of different poly anions with the first, the second and the fourth component of complement. IV. Immunology, 31,931PubMedGoogle Scholar
  5. 5.
    Diamantstein, T., Vogt, W., Rühl, H. and Bordiert, G. (1973). Stimulation of DNA synthesis in mouse lymphoid cells by polyanions in vitro. I. Eur. J. Immunol, 3,488PubMedCrossRefGoogle Scholar
  6. 6.
    Persson, U.C. J., Hammarström, L. L. G. and Smith, C. J. E. (1977). Macrophages are requiredforthedextran-sulfateinducedactivationofB-lymphocytes.J. Immonol., 119,1138Google Scholar
  7. 7.
    Schorlemmer, H. U., Burger, R., Hylton, W. and Allison, A. C. (1977). Induction of lysosomal enzyme release from cultured macrophages by dextran sulfate. Clin. Immunol. Immuno-pathol., 7, 88CrossRefGoogle Scholar
  8. 8.
    Gemsa, D., Seitz, M., Kramer, W., Till, G. and Resch, K. (1978). The effect of phagocytosis, Dextran sulfate, and cell damage on PGE, sensitivity and PGE, production of macrophages. J. Immunol., 120,1187PubMedGoogle Scholar
  9. 9.
    Schultz, R. M., Papamatheakis, J. D. and Chirigos, M. A. (1977). Interferon: An inducer of macrophage activation by polyanions. Science, 197, 674PubMedCrossRefGoogle Scholar
  10. 10.
    Schultz, R. M., Papamatheakis, J. D., Luetzeler, J. and Chirigos, M. A. (1977). Association of macrophage activation with antitumor activity by synthetic and biological agents. Cancer Res., 37,3338PubMedGoogle Scholar
  11. 11.
    Schorlemmer, H. U., Bitter-Suermann, D. and Allison, A. C. (1977). Complement activation by the alternative pathway and macrophage enzyme secretion in the pathogenesis of chronic inflammation. Immunology, 32, 929PubMedGoogle Scholar
  12. 12.
    Schorlemmer, H. U., Ferluga, J. and Allison, A. C. (1977). Interactions of macrophages and complement components in the pathogenesis of chronic inflammation. In Wil-loughby, D. A., Giroud, J. P. and Velo, G. P. (eds.) Perspectives in Inflammation, pp. 191. (Lancaster: MTP Press)Google Scholar
  13. 13.
    Ferluga, J., Schorlemmer, H. U., Baptista, L. C. and Allison, A. C. (1978). Production of the complement cleavage product C3a by activated macrophages and its tumorolytic effects. Clin. Exp. Immunol., 31, 512PubMedGoogle Scholar
  14. 14.
    Schorlemmer, H. U., Hadding, U., Bitter-Suermann, D. and Allison, A.C. (1977). The role of complement cleavage products in killing of tumour cells by macrophages. In James, K., McBride, B. and Stuart, A. (eds.) The Macrophage and Cancer, pp. 68. (Edinburgh: Econoprint)Google Scholar
  15. 15.
    Mackaness, G.B. (1970). Cellular immunity. In van Fürth, R. (ed.) Mononuclear Phagocytes, p. 461. (Oxford: Blackwell Scientific)Google Scholar
  16. 16.
    Allison, A. C., Ferluga, J., Prydz, H., and Schorlemmer, H. U. (1978). The role of macrophage activation in chronic inflammation. Agents Actions, 8, 27PubMedCrossRefGoogle Scholar
  17. 17.
    Schorlemmer, H. U., Edwards, J. H., Davies, P., and Allison, A.C. (1977). Macrophage responses to mouldy hay dust, Micropolyspora faeni and zymosan, activators of complement by the alternative pathway. Clin. Exp. Immunol., 27,198PubMedGoogle Scholar
  18. 18.
    Keller, R. (1977). Mononuclear phagocytes and antitumour resistance. In James, K., McBride, B. and Stuart, A. (eds.) The Macrophage and Cancer, p. 31. (Edinburgh: Econo-print)Google Scholar
  19. 19.
    Hibbs, J. B. (1974). Discrimination between neoplasia and non-neoplastic cells in vitro by activated macrophages.J. Natl. Cancer Inst., 53,1487PubMedGoogle Scholar
  20. 20.
    Lai A Fat, R. F. M. and van Fürth, R. (1975). In vitro synthesis of some complement components (Clq, C3 and C4) by lymphoid tissues and circulating leucocytes in man. Immunology, 28, 359PubMedGoogle Scholar
  21. 21.
    Bentley, C., Bitter-Suermann, D., Hadding, U., and Brade, V. (1976). In vitro synthesis of factor B of the alternative pathway of complement activation by mouse peritoneal macrophages. Eur. J. Immunol., 6, 393PubMedCrossRefGoogle Scholar
  22. 22.
    Schorlemmer, H. U., Davies, P., and Allison, A. C. (1976). Ability of activated complement components to induce lysosomal enzyme release from macrophages. Nature (London), 261, 48CrossRefGoogle Scholar
  23. 23.
    Ferluga, J., Schorlemmer, H. U., Baptista, L., and Allison, A. C. (1976). Cytolytic effects of the complement cleavage product, C3a. Br. J. Cancer, 34, 626PubMedCrossRefGoogle Scholar
  24. 24.
    Taylor-Robinson, D., Schorlemmer, H. U., Furr, P. M. and Allison, A. C. (1978). Macrophage secretion and the complement cleavage product C3a in the pathogenesis of infections by mycoplasmas and L-forms of bacteria and in immunity to these organisms. Clin. Exp. Immunol., 33, 486PubMedGoogle Scholar
  25. 25.
    Currie, G. A. and Basham, C. (1975). Activated macrophages release a factor which lyses malignant cells but not normal cells. J. Exp. Med., 142, 1600PubMedCrossRefGoogle Scholar
  26. 26.
    Sethi, K. K. and Brandis, H. (1975). Cytotoxicity mediated by soluble macrophage products. J. Natl. Cancer Inst., 55, 393PubMedGoogle Scholar
  27. 27.
    Sharma, S. D., Piessens, W. F., and Middlebrook, G. (1980). In vitro killing of tumour cells by soluble products of activated guinea pig peritoneal macrophages. Cell. Immunol., 49,379PubMedCrossRefGoogle Scholar

Copyright information

© MTP Press Limited 1980

Authors and Affiliations

  • H. U. Schorlemmer
    • 1
  • U. Hadding
    • 1
  • D. Bitter-Suermann
    • 1
  1. 1.West Germany

Personalised recommendations